Boston Scientific (BSX) Surges Amid Penumbra Acquisition, Analysts Bullish on Future Growth

Boston Scientific (BSX) has garnered bullish views from analysts after acquiring Penumbra. Richard Newitter from Truist Securities reiterated a Buy rating and a $120 price target, implying a 28% upside. The acquisition is expected to bolster the company's durability and support double-digit revenue and EPS growth prospects. Morgan Stanley also reiterated its positive view on the company, citing "clear catalysts" making the stock valuation highly attractive.